Comparative Efficiency of In Vivo Transfection Reagents in Mouse Organs

The efficiency of in vivo transfection in mice varies dramatically depending on the reagent formulation used and the target organ in question. Because each tissue possesses distinct physiological, structural, and biochemical barriers to nucleic acid uptake, the success of gene delivery is largely dictated by how well a reagent can navigate these hurdles. Understanding the comparative performance of lipid-based, polymer-based, and nanoparticle-based reagents across different mouse organs is essential for designing effective preclinical studies in gene modulation and RNAi therapeutics.

Lipid-based reagents are among the most widely used in vivo transfection systems due to their capacity to encapsulate nucleic acids and facilitate membrane fusion. These formulations, often composed of ionizable lipids, helper phospholipids, and cholesterol, are particularly effective in transfecting the liver and lungs. Following systemic administration via intravenous injection, lipid nanoparticles (LNPs) are efficiently taken up by hepatocytes, aided by natural apolipoprotein interactions and fenestrated endothelium in liver sinusoids. This makes lipid-based reagents a gold standard for liver-targeted gene silencing or protein expression studies in mouse models. Lung targeting is also achievable, especially when formulations are delivered intranasally or via intravenous injection with PEGylation strategies that favor pulmonary accumulation.

Polymer-based transfection reagents, such as polyethyleneimine (PEI) and biodegradable polyesters, exhibit broader organ distribution depending on charge, molecular weight, and conjugation chemistry. These reagents can transfect a wider range of tissues, including tumors, kidney, and spleen, but often suffer from increased cytotoxicity, limiting their tolerability in vivo. Their utility in tumor models—particularly in subcutaneous or orthotopic xenografts—stems from the enhanced permeability and retention (EPR) effect, which allows nanoparticles to accumulate in leaky tumor vasculature. However, optimizing polymer-to-nucleic acid ratios is essential to reduce toxicity and enhance endosomal escape.

Nanoparticle formulations, including inorganic particles (e.g., gold, silica) and organic polymer-lipid hybrids, offer customizable size, surface charge, and ligand presentation. These systems are frequently engineered for organ-specific delivery via ligand conjugation—such as GalNAc for liver or folate for tumor tissue. Encapsulation of siRNA or plasmid DNA within these vehicles provides stability against serum nucleases and facilitates tissue penetration. When combined with targeting moieties, nanoparticle-based reagents can achieve delivery to challenging sites such as the pancreas, brain, or immune organs. However, they require rigorous validation to ensure biocompatibility and avoid off-target immune responses.

Organ-specific variables must also be considered. For example, kidney and pancreas transfection is impeded by dense extracellular matrices and rapid clearance, necessitating direct local injection or use of tissue-penetrating peptides. Brain delivery is limited by the blood-brain barrier (BBB), which excludes most circulating transfection reagents unless modified with BBB-permeable ligands or delivered via intrathecal injection. In contrast, the spleen and bone marrow can be more accessible due to their role in immune surveillance, though unwanted uptake by macrophages remains a challenge.

Ultimately, no single transfection reagent achieves uniform efficiency across all mouse organs. The ideal reagent must be selected based on the anatomical location of the target tissue, the immune status of the animal, the route of administration, and the physicochemical properties of the nucleic acid payload. Empirical comparisons of different formulations—using reporter assays, histology, and gene expression analysis—are essential for determining which reagent delivers the highest efficiency and specificity for a given experimental system. These insights are not only critical for basic research but also for the translational development of RNA-based therapies targeting specific tissues in vivo.